Showing 1 - 20 results of 72 for search 'E. Yu. Loginova', query time: 0.03s Refine Results
  1. 1
    Dactylitis in psoriatic arthritis: clinical features, diagnosis, immunopathogenesis, and treatment

    Dactylitis in psoriatic arthritis: clinical features, diagnosis, immunopathogenesis, and treatment by T. V. Korotaeva, E. Yu. Loginova

    Published 2018-04-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Results of studying the clinical efficacy and safety of tofacitinib in the treatment of psoriatic arthritis

    Results of studying the clinical efficacy and safety of tofacitinib in the treatment of psoriatic arthritis by T. V. Korotaeva, E. Yu. Loginova

    Published 2019-05-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Immunopathogenetic mechanisms of action of ustekinumab, a new drug for the treatment of psoriatic arthritis and psoriasis

    Immunopathogenetic mechanisms of action of ustekinumab, a new drug for the treatment of psoriatic arthritis and psoriasis by T. V. Korotaeva, E. Yu. Loginova

    Published 2015-06-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Clinical experience with apremilast for psoriatic arthritis

    Clinical experience with apremilast for psoriatic arthritis by E. Yu. Loginova, T. V. Korotaeva

    Published 2018-09-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    EFFICACY OF CERTOLIZUMAB PEGOL IN THE TREATMENT OF PSORIATIC ARTHRITIS

    EFFICACY OF CERTOLIZUMAB PEGOL IN THE TREATMENT OF PSORIATIC ARTHRITIS by T. V. Korotaeva, E. Yu. Loginova

    Published 2015-10-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Janus kinase inhibitors in the treatment of psoriatic arthritis

    Janus kinase inhibitors in the treatment of psoriatic arthritis by E. Yu. Loginova, T. V. Korotaeva

    Published 2022-02-01
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Golimumab in the treatment of psoriatic arthritis: efficacy and safety

    Golimumab in the treatment of psoriatic arthritis: efficacy and safety by Tatiana Viktorovna Korotaeva, E. Yu. Loginova

    Published 2015-09-01
    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    Experience of guselkumab usage in the treatment of patients with psoriatic arthritis in real clinical practice

    Experience of guselkumab usage in the treatment of patients with psoriatic arthritis in real clinical practice by E. Yu. Loginova, Yu. L. Korsakova, T. V. Korotaeva

    Published 2021-10-01
    Get full text
    Article
    Save to List
    Saved in:
  9. 9
    SUCCESSFUL USE OF AN INTERLEUKIN 17 INHIBITOR (SECUKINUMAB) IN THE TREATMENT OF ISOLATED DESTRUCTIVE ENTHESITIS IN PSORIATIC ARTHRITIS

    SUCCESSFUL USE OF AN INTERLEUKIN 17 INHIBITOR (SECUKINUMAB) IN THE TREATMENT OF ISOLATED DESTRUCTIVE ENTHESITIS IN PSORIATIC ARTHRITIS by E. E. Gubar, E. Yu. Loginova, T. V. Korotaeva

    Published 2018-11-01
    Get full text
    Article
    Save to List
    Saved in:
  10. 10
    Involvement of the axial skeleton in psoriatic arthritis

    Involvement of the axial skeleton in psoriatic arthritis by E. E. Gubar, E. Yu. Loginova, T. V. Korotaeva

    Published 2017-03-01
    Get full text
    Article
    Save to List
    Saved in:
  11. 11
    Detectability of the peripheral and axial manifestations of psoriatic arthritis in patients with psoriasis in dermatological practice

    Detectability of the peripheral and axial manifestations of psoriatic arthritis in patients with psoriasis in dermatological practice by M. N. Chamurlieva, E. Yu. Loginova, T. V. Korotaeva

    Published 2019-10-01
    Get full text
    Article
    Save to List
    Saved in:
  12. 12
    DETECTION RATES OF PSORIATIC ARTHRITIS IN PATIENTS WITH PSORIASIS IN A DERMATOLOGY AND RHEUMATOLOGY CLINIC

    DETECTION RATES OF PSORIATIC ARTHRITIS IN PATIENTS WITH PSORIASIS IN A DERMATOLOGY AND RHEUMATOLOGY CLINIC by M. N. Chamurlieva, E. Yu. Loginova, T. V. Korotaeva

    Published 2016-12-01
    Get full text
    Article
    Save to List
    Saved in:
  13. 13
    Use of a multidimensional RAPID3 questionnaire to assess the achievement of remission and minimal disease activity in patients with early psoriatic arthritis treated according to Treat-to-target strategy

    Use of a multidimensional RAPID3 questionnaire to assess the achievement of remission and minimal disease activity in patients with early psoriatic arthritis treated according to T... by E. Yu. Loginova, T. V. Korotaeva, A. D. Koltakova

    Published 2019-01-01
    Get full text
    Article
    Save to List
    Saved in:
  14. 14
    Clinical and radiation diagnosis of early peripheral psoriatic arthritis (a review of literature)

    Clinical and radiation diagnosis of early peripheral psoriatic arthritis (a review of literature) by Svetlana Olegovna Krasnenko, E Yu Loginova, A V Smirnov

    Published 2012-06-01
    Get full text
    Article
    Save to List
    Saved in:
  15. 15
    Time course of changes in lipid profile measures in patients with early psoriatic arthritis during adalimumab therapy

    Time course of changes in lipid profile measures in patients with early psoriatic arthritis during adalimumab therapy by E. I. Markelova, D. S. Novikova, T. V. Korotaeva, E. Yu. Loginova

    Published 2019-11-01
    Get full text
    Article
    Save to List
    Saved in:
  16. 16
    Prognostic factors associated with achieving minimal disease activity in early psoriatic arthritis patients treated according to “treat-to-target” st rategy within 12 months

    Prognostic factors associated with achieving minimal disease activity in early psoriatic arthritis patients treated according to “treat-to-target” st rategy within 12 months by E. Yu. Loginova, T. V. Korotaeva, E. E. Gubar, S. I. Glukhova

    Published 2022-12-01
    Get full text
    Article
    Save to List
    Saved in:
  17. 17
    The duration of remission and minimal disease activity after initiation and discontinuation of biological agents in patients with early psoriatic arthritis (data from the all-russian psoriatic arthritis registry)

    The duration of remission and minimal disease activity after initiation and discontinuation of biological agents in patients with early psoriatic arthritis (data from the all-russi... by E. Yu. Loginova, T. V. Korotaeva, S. I. Glukhova, E. L. Nasonov

    Published 2019-11-01
    Get full text
    Article
    Save to List
    Saved in:
  18. 18
    Dynamics of Carotid Intima-Media Thickness, Parameters of Arterial Stiffness and Ambulatory Blood Pressure Monitoring during Therapy with Inhibitor of Tumor Necrosis Factor-Alpha in Patients with Early Psoriatic Arthritis

    Dynamics of Carotid Intima-Media Thickness, Parameters of Arterial Stiffness and Ambulatory Blood Pressure Monitoring during Therapy with Inhibitor of Tumor Necrosis Factor-Alpha... by E. I. Markelova, D. S. Novikova, T. V. Korotaeva, E. Yu. Loginova

    Published 2018-11-01
    Get full text
    Article
    Save to List
    Saved in:
  19. 19
    CLINICAL EXPERIENCE WITH USTEKINUMAB IN THE TREATMENT OF EARLY PSORIATIC ARTHRITIS USING TREAT-TO-TARGET STRATEGY

    CLINICAL EXPERIENCE WITH USTEKINUMAB IN THE TREATMENT OF EARLY PSORIATIC ARTHRITIS USING TREAT-TO-TARGET STRATEGY by E. Yu. Loginova, T. V. Korotaeva, D. E. Karateev, E. L. Nasonov

    Published 2015-09-01
    Get full text
    Article
    Save to List
    Saved in:
  20. 20
    The first results of a 6-year follow-up study of a patient with early psoriatic arthritis treated with a treat-to-target strategy

    The first results of a 6-year follow-up study of a patient with early psoriatic arthritis treated with a treat-to-target strategy by P. O. Tremaskina, E. Yu. Loginova, T. V. Korotaeva, A. V. Sukhinina

    Published 2020-09-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: